NCT06716424 - A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

April 3, 2026

Study Completion Date

April 3, 2026

Conditions

Type 2 Diabetes

Interventions

DRUG

iGlarLixi (insulin glargine/lixisenatide)

iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously

Trial Locations (9)

RECRUITING

Investigational Site Number : 3560007, Delhi

RECRUITING

Investigational Site Number : 3560003, Kanpur

RECRUITING

Investigational Site Number : 3560011, Jaipur

RECRUITING

Investigational Site Number : 3560008, Pune

RECRUITING

Investigational Site Number: 3560013, Pune

RECRUITING

Investigational Site Number : 3560006, Indore

RECRUITING

Investigational Site Number : 3560005, Hyderabad

RECRUITING

Investigational Site Number : 3560014, Visakhapatnam

RECRUITING

Investigational Site Number : 3560001, Kolkata